---
document_datetime: 2025-12-02 05:31:42
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/lokelma.html
document_name: lokelma.html
version: success
processing_time: 0.1120083
conversion_datetime: 2025-12-28 04:23:19.813605
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Lokelma

[RSS](/en/individual-human-medicine.xml/66667)

##### Authorised

This medicine is authorised for use in the European Union

sodium zirconium cyclosilicate Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Lokelma](#news-on)
- [More information on Lokelma](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Lokelma. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Lokelma.

For practical information about using Lokelma, patients should read the package leaflet or contact their doctor or pharmacist.

Expand section

Collapse section

## What is Lokelma and what is it used for?

Lokelma is a medicine used to treat hyperkalaemia (high levels of potassium in the blood) in adults. It contains the active substance sodium zirconium cyclosilicate.

## How is Lokelma used?

Lokelma is available as powder sachets (5 g and 10 g). The powder is stirred into water to make a mixture to be drunk straight away. The recommended starting dose of Lokelma is 10 g three times a day. Once the blood levels of potassium return within the normal range (usually within 1-2 days), patients should take the lowest effective dose of Lokelma to prevent the return of hyperkalaemia, starting with 5 g once a day and not exceeding 10 g once a day. For further information, see the package leaflet.

The medicine can only be obtained with a prescription.

## How does Lokelma work?

The active substance in Lokelma, sodium zirconium cyclosilicate, is a potassium binder. When taken by mouth, Lokelma attaches to potassium from food and body fluids in the gut, forming a compound that is then eliminated in the stools. This action removes potassium from the body overall, thus helping to lower the potassium levels in the blood.

## What benefits of Lokelma have been shown in studies?

Lokelma is effective at lowering blood potassium levels and keeping levels of potassium within the normal range.

In a main study of 754 patients with hyperkalaemia, 86% of patients taking Lokelma 10 g had normal potassium levels after 2 days compared with 48% of those taking placebo (a dummy treatment). In addition, when patients who had normal potassium levels after Lokelma treatment were given further treatment with either Lokelma or placebo, potassium levels stayed normal for longer with Lokelma than with placebo.

Another main study involved 258 patients who had normal potassium levels after Lokelma treatment. In this 4-week study, patients receiving further treatment with Lokelma had lower potassium levels from the second week of treatment than patients taking placebo.

## What are the risks associated with Lokelma?

The most common side effects with Lokelma (which may affect up to 1 in 10 people) are oedema (fluid build-up with swelling in the ankles and feet) and hypokalaemia (low levels of potassium in the blood).

For the full list of all side effects and restrictions with Lokelma, see the package leaflet.

## Why is Lokelma approved?

The European Medicines Agency decided that Lokelma's benefits are greater than its risks and recommended that it be approved for use in the EU. The Agency considered that Lokelma is effective at controlling blood potassium levels, especially during initial (acute) treatment. The overall safety profile is considered acceptable.

## What measures are being taken to ensure the safe and effective use of Lokelma?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Lokelma have been included in the summary of product characteristics and the package leaflet.

## Other information about Lokelma

The European Commission granted a marketing authorisation valid throughout the European Union for Lokelma on 22 March 2018.

For more information about treatment with Lokelma, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Lokelma : EPAR - Summary for the public

Reference Number: EMA/126082/2018

English (EN) (67.53 KB - PDF)

**First published:** 05/04/2018

**Last updated:** 05/04/2018

[View](/en/documents/overview/lokelma-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-304)

български (BG) (99.2 KB - PDF)

**First published:**

05/04/2018

**Last updated:**

05/04/2018

[View](/bg/documents/overview/lokelma-epar-summary-public_bg.pdf)

español (ES) (73.07 KB - PDF)

**First published:**

05/04/2018

**Last updated:**

05/04/2018

[View](/es/documents/overview/lokelma-epar-summary-public_es.pdf)

čeština (CS) (96.45 KB - PDF)

**First published:**

05/04/2018

**Last updated:**

05/04/2018

[View](/cs/documents/overview/lokelma-epar-summary-public_cs.pdf)

dansk (DA) (72.52 KB - PDF)

**First published:**

05/04/2018

**Last updated:**

05/04/2018

[View](/da/documents/overview/lokelma-epar-summary-public_da.pdf)

Deutsch (DE) (74.87 KB - PDF)

**First published:**

05/04/2018

**Last updated:**

05/04/2018

[View](/de/documents/overview/lokelma-epar-summary-public_de.pdf)

eesti keel (ET) (72.29 KB - PDF)

**First published:**

05/04/2018

**Last updated:**

05/04/2018

[View](/et/documents/overview/lokelma-epar-summary-public_et.pdf)

ελληνικά (EL) (101.79 KB - PDF)

**First published:**

05/04/2018

**Last updated:**

05/04/2018

[View](/el/documents/overview/lokelma-epar-summary-public_el.pdf)

français (FR) (73.75 KB - PDF)

**First published:**

05/04/2018

**Last updated:**

05/04/2018

[View](/fr/documents/overview/lokelma-epar-summary-public_fr.pdf)

hrvatski (HR) (91.7 KB - PDF)

**First published:**

05/04/2018

**Last updated:**

05/04/2018

[View](/hr/documents/overview/lokelma-epar-summary-public_hr.pdf)

italiano (IT) (72.6 KB - PDF)

**First published:**

05/04/2018

**Last updated:**

05/04/2018

[View](/it/documents/overview/lokelma-epar-summary-public_it.pdf)

latviešu valoda (LV) (93.98 KB - PDF)

**First published:**

05/04/2018

**Last updated:**

05/04/2018

[View](/lv/documents/overview/lokelma-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (94.61 KB - PDF)

**First published:**

05/04/2018

**Last updated:**

05/04/2018

[View](/lt/documents/overview/lokelma-epar-summary-public_lt.pdf)

magyar (HU) (92.11 KB - PDF)

**First published:**

05/04/2018

**Last updated:**

05/04/2018

[View](/hu/documents/overview/lokelma-epar-summary-public_hu.pdf)

Malti (MT) (96.73 KB - PDF)

**First published:**

05/04/2018

**Last updated:**

05/04/2018

[View](/mt/documents/overview/lokelma-epar-summary-public_mt.pdf)

Nederlands (NL) (72.8 KB - PDF)

**First published:**

05/04/2018

**Last updated:**

05/04/2018

[View](/nl/documents/overview/lokelma-epar-summary-public_nl.pdf)

polski (PL) (98.09 KB - PDF)

**First published:**

05/04/2018

**Last updated:**

05/04/2018

[View](/pl/documents/overview/lokelma-epar-summary-public_pl.pdf)

português (PT) (73.23 KB - PDF)

**First published:**

05/04/2018

**Last updated:**

05/04/2018

[View](/pt/documents/overview/lokelma-epar-summary-public_pt.pdf)

română (RO) (93.79 KB - PDF)

**First published:**

05/04/2018

**Last updated:**

05/04/2018

[View](/ro/documents/overview/lokelma-epar-summary-public_ro.pdf)

slovenčina (SK) (97.15 KB - PDF)

**First published:**

05/04/2018

**Last updated:**

05/04/2018

[View](/sk/documents/overview/lokelma-epar-summary-public_sk.pdf)

slovenščina (SL) (91.02 KB - PDF)

**First published:**

05/04/2018

**Last updated:**

05/04/2018

[View](/sl/documents/overview/lokelma-epar-summary-public_sl.pdf)

Suomi (FI) (72.36 KB - PDF)

**First published:**

05/04/2018

**Last updated:**

05/04/2018

[View](/fi/documents/overview/lokelma-epar-summary-public_fi.pdf)

svenska (SV) (72.75 KB - PDF)

**First published:**

05/04/2018

**Last updated:**

05/04/2018

[View](/sv/documents/overview/lokelma-epar-summary-public_sv.pdf)

Lokelma : EPAR - Risk management plan

English (EN) (549.92 KB - PDF)

**First published:** 07/05/2020

**Last updated:** 13/08/2025

[View](/en/documents/rmp/lokelma-epar-risk-management-plan_en.pdf)

## Product information

Lokelma : EPAR - Product Information

English (EN) (657.26 KB - PDF)

**First published:** 05/04/2018

**Last updated:** 03/09/2025

[View](/en/documents/product-information/lokelma-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-330)

български (BG) (1.78 MB - PDF)

**First published:**

05/04/2018

**Last updated:**

03/09/2025

[View](/bg/documents/product-information/lokelma-epar-product-information_bg.pdf)

español (ES) (530.16 KB - PDF)

**First published:**

05/04/2018

**Last updated:**

03/09/2025

[View](/es/documents/product-information/lokelma-epar-product-information_es.pdf)

čeština (CS) (1.57 MB - PDF)

**First published:**

05/04/2018

**Last updated:**

03/09/2025

[View](/cs/documents/product-information/lokelma-epar-product-information_cs.pdf)

dansk (DA) (1.36 MB - PDF)

**First published:**

05/04/2018

**Last updated:**

03/09/2025

[View](/da/documents/product-information/lokelma-epar-product-information_da.pdf)

Deutsch (DE) (1.44 MB - PDF)

**First published:**

05/04/2018

**Last updated:**

03/09/2025

[View](/de/documents/product-information/lokelma-epar-product-information_de.pdf)

eesti keel (ET) (1.22 MB - PDF)

**First published:**

05/04/2018

**Last updated:**

03/09/2025

[View](/et/documents/product-information/lokelma-epar-product-information_et.pdf)

ελληνικά (EL) (674.11 KB - PDF)

**First published:**

05/04/2018

**Last updated:**

03/09/2025

[View](/el/documents/product-information/lokelma-epar-product-information_el.pdf)

français (FR) (1.46 MB - PDF)

**First published:**

05/04/2018

**Last updated:**

03/09/2025

[View](/fr/documents/product-information/lokelma-epar-product-information_fr.pdf)

hrvatski (HR) (638.32 KB - PDF)

**First published:**

05/04/2018

**Last updated:**

03/09/2025

[View](/hr/documents/product-information/lokelma-epar-product-information_hr.pdf)

íslenska (IS) (1.42 MB - PDF)

**First published:**

05/04/2018

**Last updated:**

03/09/2025

[View](/is/documents/product-information/lokelma-epar-product-information_is.pdf)

italiano (IT) (1.38 MB - PDF)

**First published:**

05/04/2018

**Last updated:**

03/09/2025

[View](/it/documents/product-information/lokelma-epar-product-information_it.pdf)

latviešu valoda (LV) (1.5 MB - PDF)

**First published:**

05/04/2018

**Last updated:**

03/09/2025

[View](/lv/documents/product-information/lokelma-epar-product-information_lv.pdf)

lietuvių kalba (LT) (586.34 KB - PDF)

**First published:**

05/04/2018

**Last updated:**

03/09/2025

[View](/lt/documents/product-information/lokelma-epar-product-information_lt.pdf)

magyar (HU) (634.44 KB - PDF)

**First published:**

05/04/2018

**Last updated:**

03/09/2025

[View](/hu/documents/product-information/lokelma-epar-product-information_hu.pdf)

Malti (MT) (1.52 MB - PDF)

**First published:**

05/04/2018

**Last updated:**

03/09/2025

[View](/mt/documents/product-information/lokelma-epar-product-information_mt.pdf)

Nederlands (NL) (1.3 MB - PDF)

**First published:**

05/04/2018

**Last updated:**

03/09/2025

[View](/nl/documents/product-information/lokelma-epar-product-information_nl.pdf)

norsk (NO) (1.44 MB - PDF)

**First published:**

05/04/2018

**Last updated:**

03/09/2025

[View](/no/documents/product-information/lokelma-epar-product-information_no.pdf)

polski (PL) (1.25 MB - PDF)

**First published:**

05/04/2018

**Last updated:**

03/09/2025

[View](/pl/documents/product-information/lokelma-epar-product-information_pl.pdf)

português (PT) (588.34 KB - PDF)

**First published:**

05/04/2018

**Last updated:**

03/09/2025

[View](/pt/documents/product-information/lokelma-epar-product-information_pt.pdf)

română (RO) (2.78 MB - PDF)

**First published:**

05/04/2018

**Last updated:**

03/09/2025

[View](/ro/documents/product-information/lokelma-epar-product-information_ro.pdf)

slovenčina (SK) (610.77 KB - PDF)

**First published:**

05/04/2018

**Last updated:**

03/09/2025

[View](/sk/documents/product-information/lokelma-epar-product-information_sk.pdf)

slovenščina (SL) (720.85 KB - PDF)

**First published:**

05/04/2018

**Last updated:**

03/09/2025

[View](/sl/documents/product-information/lokelma-epar-product-information_sl.pdf)

Suomi (FI) (1.36 MB - PDF)

**First published:**

05/04/2018

**Last updated:**

03/09/2025

[View](/fi/documents/product-information/lokelma-epar-product-information_fi.pdf)

svenska (SV) (1.25 MB - PDF)

**First published:**

05/04/2018

**Last updated:**

03/09/2025

[View](/sv/documents/product-information/lokelma-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000261570 24/07/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Lokelma : EPAR - All Authorised presentations

English (EN) (31.05 KB - PDF)

**First published:** 05/04/2018

**Last updated:** 27/02/2023

[View](/en/documents/all-authorised-presentations/lokelma-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-269)

български (BG) (28.19 KB - PDF)

**First published:**

05/04/2018

**Last updated:**

27/02/2023

[View](/bg/documents/all-authorised-presentations/lokelma-epar-all-authorised-presentations_bg.pdf)

español (ES) (23.07 KB - PDF)

**First published:**

05/04/2018

**Last updated:**

27/02/2023

[View](/es/documents/all-authorised-presentations/lokelma-epar-all-authorised-presentations_es.pdf)

čeština (CS) (24.74 KB - PDF)

**First published:**

05/04/2018

**Last updated:**

27/02/2023

[View](/cs/documents/all-authorised-presentations/lokelma-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (24.2 KB - PDF)

**First published:**

05/04/2018

**Last updated:**

27/02/2023

[View](/da/documents/all-authorised-presentations/lokelma-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (25.32 KB - PDF)

**First published:**

05/04/2018

**Last updated:**

27/02/2023

[View](/de/documents/all-authorised-presentations/lokelma-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (23.27 KB - PDF)

**First published:**

05/04/2018

**Last updated:**

27/02/2023

[View](/et/documents/all-authorised-presentations/lokelma-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (26.72 KB - PDF)

**First published:**

05/04/2018

**Last updated:**

27/02/2023

[View](/el/documents/all-authorised-presentations/lokelma-epar-all-authorised-presentations_el.pdf)

français (FR) (24.25 KB - PDF)

**First published:**

05/04/2018

**Last updated:**

27/02/2023

[View](/fr/documents/all-authorised-presentations/lokelma-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (26.8 KB - PDF)

**First published:**

05/04/2018

**Last updated:**

27/02/2023

[View](/hr/documents/all-authorised-presentations/lokelma-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (23.73 KB - PDF)

**First published:**

05/04/2018

**Last updated:**

27/02/2023

[View](/is/documents/all-authorised-presentations/lokelma-epar-all-authorised-presentations_is.pdf)

italiano (IT) (24.25 KB - PDF)

**First published:**

05/04/2018

**Last updated:**

27/02/2023

[View](/it/documents/all-authorised-presentations/lokelma-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (24.93 KB - PDF)

**First published:**

05/04/2018

**Last updated:**

27/02/2023

[View](/lv/documents/all-authorised-presentations/lokelma-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (25.12 KB - PDF)

**First published:**

05/04/2018

**Last updated:**

27/02/2023

[View](/lt/documents/all-authorised-presentations/lokelma-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (24.74 KB - PDF)

**First published:**

05/04/2018

**Last updated:**

27/02/2023

[View](/hu/documents/all-authorised-presentations/lokelma-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (26.73 KB - PDF)

**First published:**

05/04/2018

**Last updated:**

27/02/2023

[View](/mt/documents/all-authorised-presentations/lokelma-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (23.75 KB - PDF)

**First published:**

05/04/2018

**Last updated:**

27/02/2023

[View](/nl/documents/all-authorised-presentations/lokelma-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (24.46 KB - PDF)

**First published:**

05/04/2018

**Last updated:**

27/02/2023

[View](/no/documents/all-authorised-presentations/lokelma-epar-all-authorised-presentations_no.pdf)

polski (PL) (27.04 KB - PDF)

**First published:**

05/04/2018

**Last updated:**

27/02/2023

[View](/pl/documents/all-authorised-presentations/lokelma-epar-all-authorised-presentations_pl.pdf)

português (PT) (23.89 KB - PDF)

**First published:**

05/04/2018

**Last updated:**

27/02/2023

[View](/pt/documents/all-authorised-presentations/lokelma-epar-all-authorised-presentations_pt.pdf)

română (RO) (33.49 KB - PDF)

**First published:**

05/04/2018

**Last updated:**

27/02/2023

[View](/ro/documents/all-authorised-presentations/lokelma-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (24.78 KB - PDF)

**First published:**

05/04/2018

**Last updated:**

27/02/2023

[View](/sk/documents/all-authorised-presentations/lokelma-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (23.88 KB - PDF)

**First published:**

05/04/2018

**Last updated:**

27/02/2023

[View](/sl/documents/all-authorised-presentations/lokelma-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (23.08 KB - PDF)

**First published:**

05/04/2018

**Last updated:**

27/02/2023

[View](/fi/documents/all-authorised-presentations/lokelma-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (23.25 KB - PDF)

**First published:**

05/04/2018

**Last updated:**

27/02/2023

[View](/sv/documents/all-authorised-presentations/lokelma-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Lokelma Active substance sodium zirconium cyclosilicate International non-proprietary name (INN) or common name sodium zirconium cyclosilicate Therapeutic area (MeSH) Hyperkalemia Anatomical therapeutic chemical (ATC) code V03AE10

### Pharmacotherapeutic group

All other therapeutic products

### Therapeutic indication

Lokelma is indicated for the treatment of hyperkalaemia in adult patients.

## Authorisation details

EMA product number EMEA/H/C/004029 Marketing authorisation holder

AstraZeneca AB

151 85 Sodertalje

Opinion adopted 26/01/2017 Marketing authorisation issued 22/03/2018 Revision 12

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Lokelma : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (164.39 KB - PDF)

**First published:** 13/08/2025

**Last updated:** 03/09/2025

[View](/en/documents/procedural-steps-after/lokelma-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Lokelma : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (210.17 KB - PDF)

**First published:** 27/06/2018

**Last updated:** 13/08/2025

[View](/en/documents/procedural-steps-after/lokelma-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Lokelma-H-C-PSUSA-00010675-202203 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Adopted

Reference Number: EMA/18088/2023

English (EN) (113.11 KB - PDF)

**First published:** 12/01/2023

[View](/en/documents/scientific-conclusion/lokelma-h-c-psusa-00010675-202203-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

## Initial marketing authorisation documents

Lokelma : EPAR - Public assessment report

Reference Number: EMA/93250/2018

English (EN) (1.58 MB - PDF)

**First published:** 05/04/2018

**Last updated:** 05/04/2018

[View](/en/documents/assessment-report/lokelma-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Lokelma

Adopted

Reference Number: EMA/CHMP/24825/2018 Rev. 2

English (EN) (62.07 KB - PDF)

**First published:** 24/02/2017

**Last updated:** 26/01/2018

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-lokelma_en.pdf)

#### News on Lokelma

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 January 2018](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-january-2018) 26/01/2018

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 February 2017](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-february-2017) 24/02/2017

#### More information on Lokelma

- [EMEA-001539-PIP01-13-M06 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001539-pip01-13-m06)
- [Non-Interventional, Exploratory, Phase IV, Single-Blind, Cross-Sectional, Randomised, Cross-over Study Evaluating Patient Palatability and Preference of 3 Potassium Binders, Sodium Polystyrene Sulphonate (SPS) or Calcium Polystyrene Sulphonate (CPS), Sodium Zirconium Cyclosilicate (Lokelma®), and Calcium Patiromer Sorbitex (Veltassa®) in Patients with Chronic Kidney Disease and Hyperkalaemia (APPETIZE) - post-authorisation study](https://catalogues.ema.europa.eu/study/49737)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 03/09/2025

## Share this page

[Back to top](#main-content)